The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

Eli Lilly and Novo Nordisk both exceeded second-quarter expectations and raised full-year guidance, yet the market’s response to their results differed significantly, highlighting growing confidence disparities between the two obesity and diabetes drug manufacturers.
Lilly reported revenue growth of 48% compared with the prior year, driven by demand for its Mounjaro diabetes treatment and Zepbound obesity drug. The company raised its full-year revenue guidance, demonstrating investor conf